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Abstract
The claudin-low molecular subtype of breast cancer is of particular interest for clinically the majority of these tumors are
poor prognosis, triple negative, invasive ductal carcinomas. Claudin-low tumors are characterized by cancer stem cell-like
features and low expression of cell junction and adhesion proteins. Herein, we sought to define the role of lipolysis
stimulated lipoprotein receptor (LSR) in breast cancer and cancer cell behavior as LSR was recently correlated with tumor-
initiating features. We show that LSR was expressed in epithelium, endothelium, and stromal cells within the healthy breast
tissue, as well as in tumor epithelium. In primary breast tumor bioposies, LSR expression was significantly correlated with
invasive ductal carcinomas compared to invasive lobular carcinomas, as well as ERa positive tumors and breast cancer cell
lines. LSR levels were significantly reduced in claudin-low breast cancer cell lines and functional studies illustrated that re-
introduction of LSR into a claudin-low cell line suppressed the EMT phenotype and reduced individual cell migration.
However, our data suggest that LSR may promote collective cell migration. Re-introduction of LSR in claudin-low breast
cancer cell lines reestablished tight junction protein expression and correlated with transepithelial electrical resistance,
thereby reverting claudin-low lines to other intrinsic molecular subtypes. Moreover, overexpression of LSR altered gene
expression of pathways involved in transformation and tumorigenesis as well as enhanced proliferation and survival in
anchorage independent conditions, highlighting that reestablishment of LSR signaling promotes aggressive/tumor
initiating cell behaviors. Collectively, these data highlight a direct role for LSR in driving aggressive breast cancer behavior.
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Introduction
Breast cancer is a heterogeneous disease that varies in its
etiology, pathophysiology and response to therapy. Breast cancer
patients with disease of similar stage and grade often respond
differently to therapy resulting in disparate clinical outcomes. In
attempts to understand the biological and clinical diversity of
breast tumors, Perou and colleagues have developed molecular
profiles characterizing the various intrinsic breast cancer subtypes,
which have been successful at prediction of overall survival,
relapse, and response to chemotherapy [1–4]. The claudin-low
subtype is of particular interest due to its aggressive behavior.
Clinically, the majority of these tumors are invasive ductal
carcinomas with a triple negative phenotype (lacking the estrogen
receptor (ER) and progesterone receptor (PR), and do not
overexpress the growth factor receptor Her2). While these tumors
initially respond to chemotherapy, there is a high risk of
recurrence, disease progression and, consequently, patient survival
is poor [5,6].
The claudin-low subtype is characterized by cancer stem cell-
like features and low gene expression of junction and adhesion
proteins including claudin 3, 4 and 7 and E-cadherin [3].
Recently, the lipolysis stimulated lipoprotein receptor (LSR) was
reported to be highly expressed in cells resistant to chemotherapy
in vitro and correlated with tumor-initiating capacity in vivo using
CD44hi/24lo epithelioid basal A cells derived from a triple
negative cell line [7]. However, the functional role of LSR in
breast cancer cell behavior has not been directly investigated.
LSR was originally identified as a hepatocyte receptor and was
shown to regulate post-prandial uptake of triacylglyceride-rich
lipoproteins [8]. LSR is involved in the dynamics of lipid
distribution between the liver and peripheral tissue, is sensitive
to high fat diets and is regulated by circulating leptin. Given the
emerging role of obesity and altered cellular metabolism in breast
cancer [9], and the recent report highlighting the role of LSR in
tumor initiating breast cancer cell populations [7], functional
studies directly testing the role of LSR in breast cancer cell
behavior were conducted.
The levels of LSR were quantified in primary breast tumor
biopsies and significant associations were identified when corre-
lated with cancer stage, pathology, and hormone receptor status.
LSR levels were significantly associated with specific intrinsic
breast cancer molecular subtypes when tested in representative
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breast cancer cell lines. Furthermore, in vitro model systems were
used to study the functional role of LSR in breast cancer cell
behavior. Our data suggest that expression of LSR may direct
collective cell migration and inhibit individual cell migration in
breast cancer cells. Overexpression of LSR in claudin-low breast
cancer cell lines re-established a family of TJ protein expression,
thereby reverting claudin-low lines to other intrinsic breast cancer
molecular subtypes. In addition, overexpression of LSR enhanced
proliferation and survival in anchorage independent conditions, as
well as significantly increased genes reported to be involved in
transformation and tumorigenesis. Collectively, these data show a




All patient samples were performed in accordance with the
guidelines of the North Carolina Central Review Board, under
protocol number 1201027. All samples were analyzed anony-
mously and were obtained de-identified from the vendor.
Cell culture
All cell lines were obtained from American Type Culture
Collection (ATCC), with the exception of SUM cell lines that were
obtained from Asterand. Cells were cultured according to
manufactures’ recommendations and passaged via trypsinization
when near 80% confluence. Primary breast epithelial cells were
previously isolated and characterized [10,11]. Cells were main-
tained in DMEM/F12 supplemented with 5% horse serum,
10 ug/ml insulin, 500 ng/ml hydrocortisone, 20 ng/ml rhEGF,
and 1% antibiotics/antimycotics. 76 N normal breast epithelial
cells were a kind gift from Dr. R. Shao (University of
Massachusetts Amherst) and maintained as described [12].
Generation of LSR-overexpressing cell lines
Myc-DDK-tagged ORF clone of Homo sapiens LSR, transcript
variant 1 was obtained from OriGene Technologies (prod:
RC223636). Cells were transfected using TurboFectin 8.0 (prod:
R0533; Thermo Scientific) according to manufacturers’ instruc-
tions. For stable transfection, cells were passaged at 1:10 dilution
into fresh growth medium containing 500–900 ug/ml of G418
(Life Technologies). Control cells were simultaneously transfected
with an empty plasmid vector and selected in antibiotics as
described above. Clonal cell lines were generated via a single cell
plated per well and expanded using the assistance of conditioned
media from the parental cell line, in addition to standard culture
conditions. Clones were evaluated for LSR expression via western
analysis prior to functional assays.
Immunohistochemistry and Immunocytofluorescence
Immunohistochemistry was performed with appropriate con-
trols as described [13]. Briefly, five mm formalin fixed paraffin
embedded tissue arrays (U.S. Biomax Inc.; arrays BR2085a and
BR805) were de-paraffinized in xylenes, rehydrated, subjected to
antigen retrieval using citrate buffer (DAKO), and staining was
performed using the Vectastain Elite ABC System (Vector
Laboratories) according to manufacturing instructions. Color
was developed with diaminobenzidine peroxidase substrate kit
(Vector Laboratories) and cores were counterstained with hema-
toxylin (Sigma Aldrich). The anti-LSR and anti-ERa antibodies
were both used at a 1:100 dilution (SC-133765; Santa Cruz
Biotechnology and NCL-ER-6F11; Lecia). LSR-antibody speci-
ficity was confirmed using an additional commercially available
antibody validated for immunohistochemistry (data not shown, Atlas
Antibodies; Stockholm, Sweden, catalogue number HPA007270).
Imaging was performed on an Olympus 1651 microscope and
quantified using NIH Image J64 software as previously described
[14] (threshold standardized; measurement determined as percent
area: red). A total of 143 invasive ductal carcinomas and 105
invasive lobular carcinomas and their associated age/menopause
status, presence or absence of ERa, and TNM status were
analyzed. ERa expression was determined by both clinical reports
with the arrays and via immunohistochemistry. Staining scores
were defined as below-detection, weak, and strong staining.
Immunocytofluorescence was performed as we previously
described [15]. Briefly, cells were grown on 8-well chamber slides
(Research Products International, Mt. Prospect, IL,) and fixed/
permeabilized in ice-cold methanol:acetone. Following fixation,
cells were blocked in 1% BSA and 5% normal horse serum PBS,
stained with the indicated primary antibody (1:100 dilution) for
one hour at 4uC (anti-LSR, SC-133765 and anti-ZO1, SC-8146,
Santa Cruz Biotechnology; anti-a-tubulin; T6199, Sigma Aldrich),
washed and then incubated for 30 minutes with an anti-rabbit,
anti-mouse or anti-goat Alexa Fluor 488 secondary antibody
(1:1000 dilution, Invitrogen). Coverslips were applied with
ProLongH Gold Antifade Reagent with DAPI (Life Technologies).
Imaging was performed on a Nikon DiaPhot microscope with
digital camera and using Spot Advanced software version 4.5
(Sterling Heights, Michigan).
Western blot analysis
Cells were lysed in RIPA Buffer (50 mM Tris Base, 150 mM
NaCl, 1 mM EDTA, 1% NP40, 0.25% sodium deoxycholate)
supplemented with protease and phosphatase inhibitors (HaltTM
Thermo Scientific). Equal protein concentrations of total cell
lysates, as determined by the Coomassie Plus Protein Assay
(Thermo Scientific), were separated by SDS-PAGE under
reducing conditions. Proteins were transferred to nitrocellulose
membranes (BioExpress). Membranes were blocked in 5% non-fat
milk in TBST (1.0 M Tris-HCL, 5.0 M NaCl, 0.1% Tween) for
1 hour at room temperature, then incubated with primary
antibody (LSR, SC133765; TIAM1 SC827; FLT1 SC316, N-
Cadherin SC271386, Santa Cruz Biotechnology; AF6 610732, BD
Transduciton Labs; Claudin7 34–1500, Occludin 33–1500,
Zymed; PKCf CST9372, Cell Signaling) overnight at 4uC in
TBST containing 5.0% BSA, washed, and incubated with the
appropriate secondary antibody conjugated to horseradish perox-
idase (GE Healthcare) in TBST with 5% milk for 1 hour at room
temperature. Mouse monoclonal a-tubulin antibody was used as a
loading control at 1:5000 dilution (T6199; Sigma Aldrich).
Enhanced chemiluminescence detection system (ECL Plus, GE
healthcare) was used to detect peroxidase activity. NIH Image J64
was used to quantify western blots.
Proliferation, Migration, Soft Agar and Tumorsphere
assays
For all assays, a minimum of three independent experiments
were performed as previously described [11]. Proliferation assays:
cells were plated in triplicate for each time point, and at the
predetermined concentration for each cell line. Manual cell counts
were taken every 24 h for a total of 120 h. Cell cycle analysis:
cultured cells in log phase growth were harvested by trypsiniza-
tion, resuspended in PBS, and fixed with 95% ethanol at 4uC for
24 h. Fixed cells were collected by centrifugation, resuspended in
staining solution (PBS, 2 mM MgCl2, 10 ug/ml RNase A,
100 ug/ml propidium iodide) and incubated at 37uC for
20 min. Single cell populations (16106 cells/ml) were analyzed
LSR in Breast Cancer
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and cell cycle analysis was performed using BD Accuri C6 Flow
Cytometer and accompanying software (Becton-Dickinson Biosci-
ence, Franklin Lakes, NJ). Migration assays: Costar transwell
permeable support 8.0 um polycarbonate membranes were used
according to the manufacturer’s protocol. Cells were washed,
resuspended in serum-free medium, and plated in the top chamber
of transwell inserts (56104 cells per insert; each line plated in
duplicate). The cells were allowed to invade through the
membrane for four to 16 h towards 10% FBS-containing medium
in the bottom chamber. Following invasion, the cells were wiped
from the top surface of the membrane; the remaining cells were
fixed in methanol and stained with a 1% toluidine blue solution.
Cell numbers were determined from microphotographs taken over
four (non-overlapping) areas of the membrane. Migration wound
assays: Cells were grown to confluence, a scratch was made with a
pipette tip, and the wound was allowed to close for up to 16 h.
Phase images were taken every 2–4 h at 10 and 20x. Image J was
used to quantify percentage of wound closure by measuring and
comparing the area free of cells at 0 hours and at 8 h. Soft agar
assays: equal numbers of cells were plated, in triplicate, on an
0.66% agarose base in a 0.33% top soft agar layer in 35 mm cell
culture dishes. Cells were incubated for 7 days and then stained
overnight with nitrobluetetrazolium. The total number of colonies
in each well was counted. Tumorsphere assays: cells were cultured
as published [16]. Briefly, cells were seeded into 24-well ultralow
attachment plates (Corning Life Sciences) containing 500 uL of
DMEM/F12 (Invitrogen) supplemented with 40 ng/mL human
epidermal growth factor (PeproTech), 20 ng/mL basic fibroblast
growth factor (PeproTech), and 2.0% B27 (Invitrogen). Cells were
sorted in the following dilutions: 50, 100, 250, 500, and 1000 cells
per well. Cells were cultured at 37uC for 10 days. Tumorsphere
growth was quantified microscopically under 20x magnification.
Transepithelial electrical resistance (TER)
Cells were plated on CostarH 0.4 mm Polycarbonate membrane
TranswellH 6-well plates and grown to confluence. Two days post
a high-density monolayer had formed the TER was measured
directly in culture medium using an epithelial volt-ohm meter
(EVOM2, World Precision Instruments). A minimum of three
independent experiments, each measured in triplicate. Results are
presented as V ? cm2. Immediately following final TER reading,
cells were directly lysed on the transwell insert in lysis buffer and
subjected to western analysis as described above.
Quantitative Real Time PCR and PCR Arrays
Total RNA was isolated from proliferating cells using the
RNeasy kit (Qiagen) according to the manufacturer’s instructions.
RNA was reverse transcribed using MMLV reverse transcriptase
(Invitrogen) and primed with oligo-dT and random hexamers
(Invitrogen). CDbGeo and pTD cDNA was amplified using gene-
specific primers for murine LSR (59-AGGCTAACCAGCAA-
GATGACTCCA-39, 39-AGGTTACTTCACTCATGGCCCG-
TT-59) GAPDH [10], SLUG and SNAIL [17]. For PCR arrays,
RNA was reverse transcribed using the RT2 Frist Strand Kit and
RT2 Profiler PCR arrays (Tight Junction; PAHS-143Z, Breast
Cancer PAHS-131Z, Qiagen) according to the manufacturer’s
instructions. Data were analyzed via the comparative CT (DDCT)
method and using the online analysis tools provided (Qiagen).
Figure 1. LSR protein expression in breast tissue and epithelial cells. (A) Representative images of normal breast tissue arrays subjected to
immunohistochemical analysis using a LSR specific antibody or corresponding negative control. Scale bar = 200 uM. (B) Representative images of
breast epithelial cells subjected to immunocytofluorescence using LSR and ZO-1 specific antibodies (DNA stained with DAPI). Control images are
primary breast epithelial cells simultaneously subjected to all steps with the exception of the addition of the primary antibody. Images were obtained
at 20X.
doi:10.1371/journal.pone.0091747.g001
LSR in Breast Cancer
PLOS ONE | www.plosone.org 3 March 2014 | Volume 9 | Issue 3 | e91747
Statistical analysis
Tumor pathology, size, presence of metastasis to primary lymph
node, and metastatic staging compared to intensity of LSR
staining was evaluated for the significance via one-way analysis of
variance (ANOVA) with the Bonferroni multiple comparisons or
Mann-Whitney post hoc analysis, or t tests using GraphPad Prism
6.0 (GraphPad Software). Age and Menopausal status compared
to intensity of LSR staining was also carried out via t tests or
ANOVA. ERa status in relation to LSR staining was visualized by
NIH Image J64 and measured by GraphPad Prism 6.0. Data was
considered significant at P,0.05. All histograms were generated in
GraphPad Prism as mean 6 S.E.M. Graphs were plotted in
Microsoft Excel as mean 6 S.D or SEM as indicated.
Results
LSR protein expression in breast tissue, breast tumor
biopsies and correlation with clinical variables
We began our investigation by evaluating LSR protein
expression levels in breast epithelial cells, breast tissue, and breast
cancer biopsies. LSR was readily detectable in the normal breast
epithelium and endotheilum, as well as evident in immune cells
and stromal tissue via immunohistochemistry (Fig. 1A). To further
detail the localization of LSR in the breast epithelium,
immunocytofluorescence was performed on primary breast
epithelial cells and normal breast epithelial cell lines (Fig. 1B).
MCF7 cells were used as a comparison of LSR localization in
cancer cells to normal breast epithelia cells and ZO-1 was used as
a control to illustrate membrane localization. Similar to results in
breast tissue histosections, LSR was primarily localized to the cell
membrane in all cells evaluated. It is of note that MCF7 cells
appeared to have a more diffused localization and higher
abundance of cytoplasmic LSR compared to normal breast
epithelium.
The relative intensity of LSR expression in the tumor
epithelium distinctly varied among patient biopsies (Fig. 2A). To
evaluate if the changes in LSR protein levels correlated with
clinical variables, the pateint samples were classifed into three
different populations based on the relative intensity of LSR
expression (below-detectable, weak, or strong) levels based on
threshold values; Fig. 2B biopsy #1 and #2, respectively for weak
and strong staining. Quantification was determined using NIH
Image J64 software (threshold standardized; measurement deter-
mined as percent area: red). Analysis of 248 breast biopies showed
that high expression levels of LSR were significantly correlated
with invasive ductal carcinomas (IDC) compared to invasive
lobular carcinomas (ILC, Fig. 2B, P,0.01). No correlation was
found between LSR expression and tumor size, age, or meno-
pausal status of the patients (Fig. S1). However, LSR expression
was found to be significantly reduced in patient samples with
lymph node invasion and distant metastasis (Fig. 2C, P,0.05).
ERa expression is known to be present in both IDC and ILC,
and the presence or absence of ERa often dictates treatment
regimen [18,19]. We next sought to correlate ERa expression with
LSR in tumor biopsies. ERa was determined via the provided
Figure 2. LSR protein expression in breast biopsies and correlation with clinical variables. (A) Representative images of breast cancer
biopsy tissue arrays subjected to immunohistochemical analysis using a LSR specific antibody or corresponding negative control. Scale bar = 200 uM.
Intensity of LSR expression in correlation with (B) breast cancer subtype IDC = invasive ductal carcinoma, ILC = invasive lobular carcinoma, (C) tumor
invasion into sentinel lymph node and/or distant metastasis, (C) ERa status in tumor biopsy, and (D) ERa status in ERa positive breast cancer cell lines
(MCF7, ZR75-1, and T47D) and ERa negative breast cancer cell lines (MDA-MD-231, SUM159, Hs578t). Data represent mean relative intensity +/2 SE.
*P,0.05, **P,0.01. A total of 248 patient samples were analyzed.
doi:10.1371/journal.pone.0091747.g002
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pathological data from each patient sample and verified via
immunohistochemistry (Fig. S2). A significant correlation was
found between tissues expressing both high levels of ERa and LSR
(Fig. 1D, P,0.005). In addition, we used representative ERa
positive and negative breast cancer cell lines to confirm our results
observed with the tumor biopsies. LSR levels were analyzed via
western analysis, and similar to tumor biopsies, a significant
correlation was observed between ERa positive cell lines and high
LSR expression (Fig. 2E P,0.001).
LSR expression in breast cancer molecular subtypes
One of the hallmarks of claudin-low molecular subtypes of
breast cancer is the absence of ERa, as well as other luminal
differentiation markers, and our data suggests that LSR is
positively correlated with ERa expression. Thus, we hypothesized
that LSR would be lost in claudin-low molecular subtypes. To test
this hypothesis, a comprehensive panel of well-characterized cell
lines from the representative molecular subtypes was analyzed for
LSR expression via western analysis (Fig. 3). LSR was readily
detectable in the majority of luminal and basal-like cell lines;
however, the claudin-low lines evaluated had significantly lower
LSR expression compared to luminal and basal-like classified cell
lines (*P,0.01). Hs578t, a highly aggressive and metastatic cell
line [20], had no detectable levels via western analysis. Collec-
tively, these data support our tumor biopsy data in that LSR
expression varies by subtype, with decreased levels in subtypes
associated with poor prognosis.
Reintroduction of LSR into a claudin-low breast cancer
cell line and the resultant effect on cell behavior
To begin to understand the role of LSR in directing cell
behavior, we reintroduced LSR into the Hs578t claudin-low breast
cell line (LSR+) that had undetectable levels of LSR via western
blot analysis (Fig. 4A, B). Cell morphology was noticably changed
upon confirmed expression of LSR; the overall cell size of LSR+
cells appeared reduced, and LSR+ cells grew in distinct clusters
compared to pCMV control cells (Fig. 4C) when plated at similar
densities/equivalent cell numbers.
The localization of LSR expression was predominatly on the
cell membrane, however, similar to the pattern in the MCF7
cancer cell line (Fig. 1B) LSR was also prominent in the cytoplasm.
Interestingly, reintroduction of LSR resulted in a signifincat
increase in proliferation rate compared to control cells (Fig. 4D,
left; *P,0.001). Cell cycle anlaysis revealed that LSR+ cells had a
shift in cell cycle towards S and G2/M phase compared to control
cells (Fig. 4D, right; P,0.02). Correspondingly, LSR+ cells had a
significant decrease in the percentage of cells in the G0/G1 phase
(P,0.03). Together these data suggest reintroduction of LSR
expression in Hs578t claudin-low cells alters cell behavior,
including cell morphology and proliferation.
We next performed functional assays to direclty test the effect of
LSR on breast cancer cell behavior. Although increased prolifer-
ation suggested a more aggressive cell behavior, LSR expression
caused a signficant decrease in the ability of individual cells to
migrate through a porous membrane towards a chemoattractant
(Fig. 5A; *P,0.001). In addition, wound healing scratch assays
revealed an altered capacity for cells to migrate and close a wound
depending on the expression of LSR, as LSR+ cells closed the
induced scratch at a slower rate compared to control cells (Fig. 5B;
*P,0.01). Noteably, the phenotype and migratory behavior of the
LSR+ cells during wound healing was indicative of collective cell
migration. The control cells closed the scratch via individual cells
migrating into the wound, while the LSR+ cells moved as a
collective whole, budding into the wound (Fig 5C). The phenotype
is similar to the morpholgy observed during the migration of the
terminal ductal lobular structures into the adipose tissue during
pubertal development [21].
Thus, to further investigate the role of LSR in migratory
behavior we utilized a validated epithelial-to-mesenchymal (EMT)
mammary cell line system to observe the relative expression of
LSR in both the epithelial and mesenchymal phenotypes of the
same parental cell line (CDbGeo and pTD for ‘‘persistently trans-
differentiated cells’’, respectively) [17]. As shown in Fig. 5D, the
pTD that have been transformed by TGFb, and exhibit a
mesenchymal phenotype, express significantly lower LSR levels
compared to control cells. EMT was confirmed by increases in
SLUG and SNAIL in the TGFb stimulated cells. Collectively these
data suggest that the expression of LSR reduces individual
migratory cell behavior. However, the enhanced proliferative
capacity and collective migration of the cells warranted further
analyses.
We challenged the pCMV and LSR+ cells to grow in
anchorage-independent conditions, thereby mimicking changes
that occur during tumorigenesis. Soft agar transformation assays
revealed that expression of LSR significantly enhanced the ability
of individual cells to survive and form colonies on soft agar
(Fig. 6A, *P,0.001). Next, sphere formation assays were
performed to determine if the expression of LSR enhanced
survival, self-renewal, and growth in suspension culture. Results
show that individual LSR+ cells were able to form tumorspheres at
densities as low as 50 cells/ml compared to control cells which
only formed sphere starting at 500 cells/ml (Fig. 6B). Corre-
Figure 3. LSR expression in breast cancer molecular subtypes.
Representative breast cancer cell lines were grown to 80% confluence,
lysates were isolated and analyzed via western analysis using a LSR
specific antibody; a-tubulin was used as a loading control. (A, B)
Representative western blot and corresponding intensity measured via
ImageJ. (C) Analysis based on molecular subtype of cell lines. Data
represent mean relative intensity +/2 SE. **P,0.01.
doi:10.1371/journal.pone.0091747.g003
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sponding with our results of enhanced proliferation of LSR+ cells
on tissue culture dishes, we observed that the spheres formed from
the LSR+ cells were larger in diameter compared to spheres
formed from pCMV cells after seven days of growth.
To rule out clonal variabilty, three clonal cell lines with varying
levels of LSR expression were established and tested (Fig. S3).
Similar to results with polyclonal colonies, LSR+ clones had
reduced cell size and altered morphology, enhanced proliferation,
reduced individual cell migration, and enahnced survival and self-
renewal/growth in non-adherent condtions compared to controls.
The intensity of the observed cell behaviors corrrelated with LSR
expression levels in a dose dependent manner; the higher the
expression of LSR the more robust the cellular response.
Given the dramatic phenotype and behavioral changes
observed with overexpression of LSR in a claudin-low cell line,
we performed a pathway targeted PCR array analyses to gain
further insight into the global gene expression changes upon
reintroduction of LSR. Results show that reintroduction of LSR
was able to collectivley reestablish the expression of a significant
number of tight junction, cell adhesion, and cytoskeletal-activity
related genes (Fig. 7A). Thus, we investigated whether LSR
expression correlated with barrier function in the LSR+ cell lines
and normal breast epithelal cells. Monolayers of cells plated on
transwell inserts were tested two days post reaching high-density
confluence. MCF7 cells served as a positive control as they are
known to exhibit high levels of transepithelial electrical resistance
(TER) [22–24]. Both primary breast epithelial cells and normal
breast cancer cell lines demonstrated TER, though the levels were
reduced compared to the MCF7 cells (Fig 7B). LSR+ cells
demonstrated lower, but detectable level of TER while pCMV
control cells had no detectable levels of TER. The level of LSR
was comparable between MCF7 and normal breast epithelial cells;
however, the shift in molecular weight may suggest different
variant or post-translational modifications of LSR. Wildtype
Hs57st and SUM159 cells also had no detectable levels of TER
(data not shown), consistent with their claudin-low subtype and lack
Figure 4. LSR expression in a claudin-low breast cancer cell line. Hs578t cells were stably transfected with either a control plasmid (pCMV), or
a plasmid containing the full-length gene for LSR variant 1 (LSR+). Cell lines were grown to 80% confluence; lysates were isolated and analyzed via
western analysis using and LSR specific antibody and a-tubulin for loading control. Intensity measured via ImageJ. (A) Representative western blots.
(B) Data represent mean relative intensity +/2 SE. *P,0.001. (C) Representative images of cells growing on tissue culture treated dishes (left panels;
206 magnification) and cells subjected to immunocytofluorescence using a LSR specific antibody (right panels; DNA stained with DAPI, 406
magnification). (D) Proliferation assays. Cells were plated at 50,000 cells per well in triplicate and counted every 24 h for 96 h. Data represent mean +/
2 SE. *P,0.001. (E) Cell cycle analysis: cells growing in log-phase were fixed and stained with propidium iodine and analyzed via flow cytometry. Data
represent mean +/2 SE. *P,0.03.
doi:10.1371/journal.pone.0091747.g004
LSR in Breast Cancer
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of LSR expression (Fig. 3A). These data suggest that re-
introduction of LSR may promote an overall differential activation
of cytoskeletal/membrane protein transcriptome.
Analysis of the cancer-targeted PCR array similarly show an
increase in cytoskeletal and adhesion genes (Fig. 7C). In addition,
we observed an increase in several cell cycle genes (Cyclin D2,
PIN2, MCM2, CDK4) confirming our observation that LSR+
cells had increased cell prolieration (Fig. 4D). It is of note that the
expression levels of several cellular metabolism genes were
significanly altered including LPL and CPT1, a protein that
functions in mitochondria oxidation of long chain fatty acids.
Moreover, in accord with our observations on suppression of EMT
in LSR+ cells, a decrease in N-cadherin, angiopoietin-2, IGFBPs,
CCL2, FOXC2, VEGFC, and keratin 14 transcript abundance
was observed in LSR+ cells.
To confirm results from the arrays, a selection of differentially
regulated genes were analyzed via western blot analysis to
observed changes in protein expression between the two cell lines.
As show in Fig. 7D, the pattern of protein regulation in the LSR+
cells compared to controls followed the results in the array with all
proteins tested. Collectivley, these data highlight a collection of
pathways for future analysis of LSR function in breast cancer.
Discussion
In the current study, we show a funtional role for LSR in
directing breast cancer cell behavior. Collectively, our breast
cancer biopsy analyses suggest that LSR expression is correlated
with a less aggressive tumor phenotype. Indeed, our functional
studies illustrated that that reintroduction of LSR into a highly
invasive cell line suppressed the EMT phenotype, as well as in an
independent mammary cell culture model of EMT, and that LSR
expression reduced cell migration in vitro. However, while
expression of LSR reduced the EMT phenotype in breast cancer
cells, the high rate of proliferation, escape from anoikis, and the
observed collective cell migration behaviors of LSR-containing
cells suggests that tumors containing LSR may indeed display an
aggressive cancer phenotype. The requisite in vivo studies are
currently being performed in our laboratory, however, a recent
study evaluating the functional hetergeneity of breast cancer stem-
like cells correlated high levels of LSR in breast cancer cells with
tumor initiating properties [7]. The authors used a triple-negative
breast cancer cell line with a known bi-lineage phenotype to isolate
single cells containing high levels of CD44 that exhibited
mesenchymal/basal B and luminal/basal A features, respectively.
They show that rather than the CD44hi/CD242 mesenchymal-
like basal B cells, the CD44hi/CD24lo epithelioid basal A cells
Figure 5. Effect of LSR expression on breast cancer migratory cell behavior. Hs578t cells were stably transfected with either a control
plasmid (pCMV), or a plasmid containing the full-length gene for LSR variant 1 (LSR+). (A) Cell migration: Cell were allowed to migrate through
transwell inserts towards media containing 10% serum for up to 16 h then fixed, stained and counted (left; representative image of migrated cells,
right; quantitation). (B) Wound assay: Cells were grown to confluence, and then a scratch was induced down the middle of the monolayer. Cells were
imaged at every four h for 16 h. Data represent mean +/2 SE of percent wound closure at eight h (10X). (C) Representative images of cell behavior
during wound closure at 20X. (D) Quantitative RT-PCR analysis of validated cell line model system that comparing control (CDbGeo) and the
terminally differentiated EMT phenotype (pTD) for LSR expression. SNAIL and SLUG were evaluated to confirm EMT.
doi:10.1371/journal.pone.0091747.g005
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retained classic cancer stem cell features such as tumor-initiating
capacity in vivo, mammosphere formation and resistance to
standard chemotherapy. These tumor-initiating cells also corre-
lated with higher expression levels of LSR compared to
mesenchymal/basal B cells.
Our present study complements these findings and extends the
research to show direct functional mechanisms of LSR on cell
behavior. We similarly observed that LSR containing cells are
more epithelioid and have an increased ability to self-renew,
survive and grow in anchorage independent conditions. We also
directly show the alterations in cell behavior are recapitulated
when LSR is reintroduced in a triple-negative cell line. Interest-
ingly, we found that LSR expression significantly correlated with
ERa expression in breast cancer biopsies as well as decreased
metastasis, while the CD44hi/CD24lo study used LSR in their 31
prognostic gene signature to predict distant metastasis [7]. In the
present study, we did not find any correlation between LSR
expression and distant metastasis in ERa negative tumor biopsies
(data not shown), suggesting that a multiple gene signature is a more
faithful predictor for metastasis.
Reports by Furuse and colleagues have recently shown a
distinct, tricellular localization of LSR in the EpH4 murine
mammary clonal cell line and other non-mammary epithelial
tissues [25–28]. Our data show in the normal breast epithelial
cells, non-transformed breast epithelial cell lines, as well as the
polyclonal and clonal LSR+ cells exhibited a less defined pattern,
with LSR localization to the membrane and even found in the
cytoplasm, as opposed to only distinct tricellular tight junctions.
The method of visualization or selection of the clonal cell lines/
generation of knockdown and rescue EpH4 cells may reflect one
possibility of these differential observations. However, two recent
reports support our data showing that LSR localizes to regions
other than tricellular tight junctions in the endothelium of various
tissues [28,29]. Our array data also show a set of signaling proteins
reestablished upon LSR overexpression, suggesting the potential of
additional cellular functions directed by activation of LSR.
Consistent with other reports, our data show the expression of
LSR was correlated with increased barrier function. However, our
data suggest this correlation may be due to the role of LSR in re-
establishing the expression of tight junction and adhesion proteins,
as we do not directly show LSR modulating barrier function or
specific tight junction localization. While additional studies are
warranted, the possibility exists that tissue specific factors may
promote a more generalized membrane-signaling role for LSR in
breast tissue, and that activation of LSR signaling drives a re-
programming of the transcriptome potentially through the
downstream activation of transcription factors. Indeed LSR has
been shown to bind to 14-3-3s in HEK293 cells using affinity
capture and proteomic analysis [30], and was shown to directly
bind lactoferrin in ligand blot assays [31] highlighting a multitude
of signaling possibilities for LSR in a tissue specific context.
LSR was originally identified as a hepatic receptor involved in
the regulation of postprandial lipemia [32]. In hepatic tissue, LSR
undergoes conformational changes upon activation by free fatty
acids, thereby revealing binding sites for apoB and apoE proteins
and promoting endocytosis [8,32–34]. We observed changes in
several metabolism-related genes upon reintroduction of LSR
including glucose-6-phosphate dehydrogenase, carnitine palmi-
toyltransferase 2, and LPL (Fig. 6). Given the hepatic role in of
LSR in lipid endocytosis, it is possible that LSR expression altered
the cellular metabolism, allowing for the observed enhanced
proliferation. It is well known that highly proliferative cancer cells
undergo fundamental changes in metabolism, with increased
glucose update and glycolysis [35–38]. Moreover, changes in the
lipid profile of a cell drastically affect cellular metabolism and
signal transduction. In relation to cancer, upregulation of lipid
metabolism is often observed during the early stages of neoplasia
and is a recognized hallmark of many types of cancer [39]. A
future goal of our research is to delineate the alterations in breast
cancer cellular metabolism with varying levels of LSR expression.
Lastly, elevated postprandial lipemia is often associated with
obesity, a confounding factor in the development and progression
Figure 6. LSR enhances cell survival in non-adherent culture conditions. Hs578t cells were stably transfected with either a control plasmid
(pCMV), or a plasmid containing the full-length gene for LSR variant 1 (LSR+). (A) Soft agar assays. Cells were plated on soft agar coated wells, grown
for seven days, then stained with nitrobluetetrazolium before counting. The entire dish was analyzed and colonies larger than 50 um in diameter
were counted. Data represent mean colonies counted per well 6 SE of three separate experiments; *P,0.001. Bottom panels are representative
images at 10X. (B) Sphere forming efficiency. Cells were plated in DMEM +10 ng/ml EGF +20 ng/ml FGF +2% B27 in ultralow attachment dishes for
seven days then spheres counted and imaged. Data represent mean +/2 SD of three independent experiments at the indicated cell plating densities.
Bottom panels are representative phase images of anchorage-independent, single-cell derived spheres from LSR+ and control pCMV cells after seven
days of growth. Scale bar, 50 um.
doi:10.1371/journal.pone.0091747.g006
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of breast cancer. The obesity-linked adipokine, leptin, is a well-
known mitogen/survival factor in breast cancer cells [40], and has
been shown to upregulate hepatic LSR levels and ultimately
control of hepatic uptake of lipids in vivo [34]. It would be of
interest to explore whether metabolic status affects levels of LSR in
extra-hepatic tissues, including the breast as well as the intracel-
lular changes that occur upon LSR expression.
In conclusion, our data illustrate novel insight into the
multifaceted role of LSR in directing breast cancer cell behavior.
We show that reintroduction of LSR into breast cancer cells is able
to stimulate the expression of genes involved in transformation and
tumorigenesis, a family of tight junction/cell adhesion proteins, as
well as enhance cellular proliferation and survival in anchorage
independent conditions. The reintroduction of LSR into claudin-
low breast cancer cells presents a unique model system to study
cancer-stem cell characteristics, metabolic driven changes in breast
cancer behavior, as well as the intercellular mechanisms that drive
the transition between breast cancer molecular subtypes.
Supporting Information
Figure S1 LSR protein expression in breast biopsies
and correlation with clinical variables. Breast cancer biopsy
tissue arrays were subjected to immunohistochemical analysis
using a LSR specific antibody or corresponding negative control.
Intensity of LSR expression in correlation with (A) tumor grade,
(B) patient menopausal status (premenopausal age 18 to 44 peri-
menopausal range 45–53; [41]), and (C) age. Data represent mean
relative intensity +/2 SE. *P,0.05, **P,0.01. A total of 248
patient samples were analyzed.
(TIF)
Figure 7. Re-introduction of LSR alters tight junction and breast cancer related gene expression. Hs578t cells were stably transfected
with either a control plasmid (pCMV), or a plasmid containing the full-length gene for LSR variant 1 (LSR+). Quantitative real-time PCR analysis was
performed for genes associated and with tight junctions and adhesion proteins (A). Data show representative scatterplots and corresponding list of
genes significantly altered by expression of LSR. (B) Transepithelial Electrical Resistance in breast epithelial cells and breast cancer cells +/2 LSR
expression. Cells were plated on transwell inserts and grown to confluence. Two days post formation of a high-density monolayer TER was measured
directly in culture medium. Cell monolayers were directly lysed on the transwell insert following final TER measurement and subjected to western
analysis using an LSR specific antibody. Tubulin was used as a loading control. Date represent a minimum of three independent experiments, each
measured in triplicate. (C) Quantitative real-time PCR analysis was performed for genes associated and with deregulation in cancer. Data show
representative scatterplots and corresponding list of genes significantly altered by expression of LSR. (D) Representative western blots highlighting
protein level changes of a panel of genes found to be differentially expressed in the arrays.
doi:10.1371/journal.pone.0091747.g007
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Figure S2 ERa protein expression in breast biopsies.
Breast cancer biopsy tissue arrays were subjected to immunohis-
tochemical analysis using an ERa specific antibody or corre-
sponding negative control. Scale bar = 200 uM. A total of 248
patient samples were analyzed.
(TIF)
Figure S3 LSR+ Clonal Cell Lines and Functional
Assays. Hs578t cells were stably transfected with either a control
plasmid (pCMV), or a plasmid containing the full-length gene for
LSR variant 1 (LSR+). Clonal cell lines were generated via a single
cell plated per well and expanded using the assistance of
conditioned media from the parental cell line, in addition to
standard culture conditions. (A) Western analysis confirmation of
LSR expression. (B) Representative images of immunocytofluor-
escence using a LSR specific antibody (DNA stained with DAPI).
(C) Proliferation assays: cells were plated at 50,000 cells per well in
triplicate and counted every 24 h for 96 h. Data represent mean
+/2 SD. *P,0.01. (D) Sphere forming efficiency: cells were
plated in DMEM +10 ng/ml EGF +20 ng/ml FGF +2% B27 in
ultralow attachment dishes for seven days then spheres counted
and imaged (scale bar, 50 um). (E) Soft agar assays: cells were
plated on soft agar coated wells, grown for seven days, and then
stained with nitrobluetetrazolium before counting. The entire dish
was analyzed and colonies larger than 50 um in diameter were
counted. Data represent mean colonies counted per well 6 SD;
*P,0.001. Top panels are representative images at 20X. (F) Cell
migration: Cell were allowed to migrate through transwell inserts
towards media containing 10% serum for up to 16 h then fixed,
stained and counted (top; representative image of migrated cells,
bottom; quantitation). Data represent mean number of cells
counted per field 6 SD; *P,0.001.
(PDF)
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